The Healthcare Technology Report is pleased to announce and recognize a unique set of accomplished women playing vital roles in some of the most important global companies shaping the future of biotechnology. The awardees of 2019 were each selected based on a detailed review of the depth of their professional experience and the caliber of their career achievements. These women are leaders not only in title or position but based on what they’ve been able to accomplish inspiring the teams and organizations around them. They have also demonstrated a commitment to the advancement of biotech. We congratulate each of this year’s awardees of The Top 25 Woman Leaders In Biotech of 2019.
1. Heather Bresch
Chief Executive Officer
The first woman to run a Fortune 500 pharmaceutical company, Heather Bresch is a force to be reckoned with. The daughter of former West Virginia Governor and current US Senator, Joe Manchin, Heather is no stranger to power and success, but forging her own path in biotech has seen the business executive excel to new heights. During her 28-year stint at Mylan, a generic drug company, Heather went from working an entry-level position in the quality control department of a factory in Morgantown to becoming one of their most successful CEOs. As CEO of Mylan, she’s continued to advocate for more regulation of the pharmaceutical industry by the FDA and was recognized by Esquire in 2011 as one of their "Patriots of the Year" for championing the issue. In 2014, she was named one of Fortune’s "50 Most Powerful Women In Business.” Most notably, Heather has completely transformed Mylan into a generics giant. When she first started, the company employed 300 people and boasted $100 million per year, compared to three decades later, where Mylan collects over $20 billion in annual revenue from 165 countries.
2. Angela Hwang
Group President, Biopharmaceuticals Group
Angela Hwang is the Group President of the Pfizer Biopharmaceuticals Group and a member of the company’s Executive Leadership Team.
In this role, she leads all of Pfizer’s innovative medicines businesses; a global organization that operates in more than 125 countries, with a portfolio of more than 600 products generating approximately $38 billion in 2018 revenues for Pfizer. It encompasses six global businesses: Oncology, Inflammation & Immunology, Rare Disease, Vaccines, Internal Medicine, and Hospital; and an Emerging Markets group. Each of these areas supports a robust innovative pipeline, and partners with Pfizer’s research and clinical development teams to bring breakthrough medicines to market.
Previously, Angela was the Group President of Pfizer Essential Health, a leader in non-viral Anti-Infectives, Biosimilars, off-patent Sterile Injectables, and the Emerging Markets. Its Global Brands portfolio included many of Pfizer’s most iconic brands, including Lipitor, Viagra, and Norvasc.
Angela joined Pfizer in 1997 and has held more than 10 different positions spanning strategy, product development, marketing, sales, and general management. Her experience covers a wide array of therapeutic areas and medicines in all stages of their lifecycle, as well as geographical breadth in both developed and emerging markets.
3. Pia D'Urbano
Corporate Vice President Biopharmaceuticals
Since joining Biopharmaceuticals for Novo Nordisk in January 2018, Corporate Vice President Pia D’ Urbano has led the US commercial team. Leading the charge in treatments for people with rare bleeding disorders like hemophilia, as well as growth hormone-related diseases, diabetes, and obesity, Novo Nordisk’s shares have gained 9% over the past three months. At the helm is D’Urbano, who with 24 years of healthcare business experience has guided the direction and alignment of marketing and sales strategies with the purpose of not only improving access to treatment and care but also educating key stakeholders and customers of these conditions. Launching brands domestically and globally, across the US, Japan, Europe, South America, and Canada, D'Urbano's expert ability to initiate and effect change is unmatched. Prior to joining Novo Nordisk, D’Urbano played major roles at Sanofi Pharmaceuticals as Vice President and Head of US Public Affairs & Advocacy, Bristol-Myers Squibb as the Head of Neuroscience and Global Marketing Director, and GlaxoWellcome as their Hospital and Primary Care Medical Representative.
4. Grainne Quinn, M.D.
Executive Vice President & Chief Medical Officer
Dr. Grainne Quinn, M.D., was selected as Executive Vice President of Perrigo Company plc in July 2016, and Chief Medical Officer in November 2015. A leading provider of over-the-counter health and wellness pharmaceuticals, Perrigo is based in Ireland, while 70% of the company’s net sales come from the US. Responsible for all product safety, clinical affairs, and quality compliance aspects for the company, Quinn is motivated by her unwavering dedication to patient safety. Before joining Perrigo, she served as Chief Medical Officer, Vice President and Head of Global Pharmacovigilance and Risk Management at Elan and spent seven years at Quintiles Ireland Ltd., where she sustained several leadership positions, including Executive Director, Medical and Scientific Services, and Global Head of Safety Physicians. Board Certified in Internal Medicine in 1995, she earned her medical degree from the Royal College of Surgeons in Ireland. Dr. Quinn then practiced in the United States for many years prior to joining the pharmaceutical industry.
5. Ginger Gregory, Ph.D.
Chief Human Resources Officer
Ginger Gregory has held executive-level positions for several multinational companies across a variety of industries. This includes Chief Human Resources Officer at Dunkin' Brands, Global Head of Human Resources at Novartis Vaccines and Diagnostics, and Chief Human Resources Officer at Shire Pharmaceuticals. Today, she’s the Chief Human Resources Officer at Biogen, a pioneer and leader in biotechnology. With a resume this impressive, it seems likely that Gregory had her entire career mapped out, but the opposite is actually true. While attending college, Gregory took a chance and majored in psychology, eventually earning a Ph.D. in Industrial and Organizational Psychology at George Washington University. Having served on the Executive Committee at Biogen since 2017, she leads the company’s global HR function and organizational strategy. Bringing more than 20 years of experience to the company, Gregory’s knowledge of organizational optimization as well as the inner workings of the industry is a most significant asset to a company as fundamental to biotech advancements as Biogen.
6. Sheila Gujrathi, M.D.
Co-Founder, Chief Executive Officer
As the former chief medical officer of Receptos, a small biotech company Dr. Sheila Gujrathi was left feeling "bittersweet" after the company was acquired by Celgene. However, this left Gujrathi, former CEO of Receptos Faheem Hasnain, and a few of their colleagues open to start “the company of our dreams.” This is the origin story of Gossamer Bio, of which Gujrathi is the co-founder and CEO. Launched in January 2017, the biotech startup, which specializes in developing drugs for immunology went public this year. In just 13 months the San Diego-based company has raised close to $600 million dollars. With roles as the Vice President of the Global Clinical Research Group in Immunology at Bristol-Myers Squibb between 2008 to 2011, as well as a stint at Genentech from 2002 to 2008 where she held roles across the Immunology, Tissue Growth and Repair clinical development group and served as the Avastin Franchise Team Leader, it’s clear that this former physician has a burning desire to further develop the biotech arena.
7. Tina Hunt, Ph.D.
Corporate Vice President and General Manager, VetLab, Diagnostic Imaging, and Telemedicine
Dr. Tina Hunt joined IDEXX, a global leader in veterinary diagnostics, software, and water microbiology testing, in 2006. The Maine-based biotech company enhances veterinarians’ ability to provide advanced medical care, improve staff efficiency, and build more economically successful practices in more than 175 countries. Just ten years later, in 2016 she became Corporate Vice President. An integral part of the company, Dr. Hunt’s career at IDEXX has spanned various leadership roles, most notably leading the VetLab organization as Vice President and General Manager, spearheading the expansion of market-leading veterinary diagnostic analyzers and assays for a growing and increasingly complex global market. Under Dr. Hunt’s leadership, the company has been gaining investors’ confidence on consistently favorable performance, with its shares outperforming its industry over the last year. She holds a Ph.D. in environmental engineering from Purdue University and an MBA from the University of Southern Maine. Before joining IDEXX, Dr. Hunt served as Vice President at Woodard Curran, leading the firm's litigation support practice.
8. Trudy Stein
Executive Vice President and Chief Human Resources Officer
As the Executive Vice President and Chief Human Resources Officer for IQVIA, Trudy Stein has implemented her expansive experience to ensure strong alignment of the company's HR strategies with their programs at large. Following the merger of Quintiles and IMS Health, Stein was named for the executive position at IDVIA in October 2016. Previously serving as IMS Health's Vice President, which she joined in 2008, Stein has held a number of roles, which include managing mergers and acquisitions at American Express; Senior Manager of Human Resources at Pfizer Pharmaceuticals; and Vice President and Director of Human Resources at CIT Financial Services, where she provided strategic support to the healthcare, communications, media and technology, asset-based lending and aerospace/rail businesses. Applauded for her efforts which create "real-world results," Stein is a motivated and effective leader with an ability to lead diverse teams to success. She holds a Bachelor of Science in Business Management from St. Cloud State University.
9. Aradhana Sarin, M.D.
Executive Vice President, Chief Strategy and Business Officer
At the beginning of 2019, Dr. Aradhana Sarin’s was tapped for her current role, which was announced by Alexion's former CFO, Paul Clancy. She had joined the company in 2017 as their Senior Vice President, Business Development and Corporate Strategy. The global biopharmaceutical company focuses on serving patients and families affected by rare diseases by discovering, developing, and commercializing life-altering solutions. Coming in at such a crucial time, Dr. Sarin is marked to help the company size up more acquisitions, after negotiating $2 billion worth of deals in her time with the company. Bringing more than 20 years of experience to Alexion, Dr. Sarin’s knowledge spans global healthcare systems, an excellent understanding of the biopharmaceutical sector, and extensive transactional experience. Leading the company’s disciplined business development efforts, she has overseen five business development deals critical to rebuilding Alexion’s pipeline and has ensured that the company is positioned to meet requirements for its refocused corporate strategy. Prior to joining Alexion, Sarin worked as the Managing Director of Healthcare Investment Banking at Citi and spent six years at UBS Investment Bank in varying senior roles, and as an Investment Banking Associate at JPMorgan between 2000 and 2001.
10. Sandra Horning, M.D.
Executive Vice President, Global Development and Chief Medical Officer
Cancer survivor and noted physician-scientist, Dr. Sandra Horning has a long distinguished career in cancer treatment and research. Horning joined Genentech in 2009 at a pivotal moment for the company, coinciding with Roche's $47 billion buyout. She became Executive Vice President, Chief Medical Officer and Global Head Of Product Development in January 2014. Spanning a decade with Genentech, first as their global head of oncology and hematology, Horning has been a key player in bringing 15 new drugs to patients. In April this year, she announced her retirement, officially set for December 31. While her career has been marked by some of the toughest diseases, including cancer, multiple sclerosis, influenza, and blindness, Horning’s legacy is that of a tenacious leader, striving for new innovations in the face of illness. Previously a tenured professor at Stanford University School of Medicine, Horning spent 25 years as a practicing oncologist, investigator, and professor before her move to Genentech.
11. Hafrun Fridriksdottir, M.D.
Executive Vice President, Global R&D
Dr. Hafrun Fridriksdottir, Teva’s Executive Vice President, Global R&D is positive in every move she makes. “I don’t regret any step I have taken in my career,” says Dr. Fridriksdottir. “If I had to start over again, I don’t think I would do anything differently.” Taking the lead on Teva Pharmaceutical’s renewed focus on generic drugs, she has played a prominent part in the company’s recent shakeup. Before joining Teva, Dr. Fridriksdottir worked as Senior Vice President and President of Global Generics R&D in Allergan plc, Senior Vice President, R&D at Actavis Group, and as Divisional Manager of Development at Omega Pharma. A strong advocate for more women in senior management roles, Dr. Fridriksdottir says that "sometimes you need to make sacrifices. In many women’s minds, they can’t do it because they have to take care of the family, so they don’t put themselves forward." She holds an MS degree in pharmacy and a Ph.D. in physical pharmacy from the University of Iceland.
12. Pascale Richetta, M.D.
Executive Vice President, Head of the Bone Patient Value Unit
Despite starting her career as a physician, Dr. Pascale Richetta found her calling in pharma initially at home in France, at Servier and Ipsen Biotech. “I loved working in this space,” said Richetta. “It meant, I could be hands-on in helping develop new medicines and solutions for patients in a scientific setting.” Today she's the Executive Vice President and Head of the Bone Patient Value Unit at UCB, in Belgium. With a focus on neurology and immunology disorders, UCB leverages scientific advancements in genetics, biomarkers, and biology to create cutting-edge drugs and practical solutions. Richetta’s role, however, is much more specific. “My main aim is to take UCB's investigational osteoporosis medicine, which is being co-developed with Amgen, through its development phases, and upon regulatory approval ensure we are prepared for its worldwide launch.” Bringing over 20 years in pharma to the company in 2016, the University of Poitiers graduate also has spent time as Vice President at Abbvie/Abbott, as well as at GlaxoSmithKline, Ipsen, and Servier. As an industry thought leader, Richetta’s commercial experience in pharma, complex biologics, and global markets are key to UCB’s future.
13. Paula Swain
Executive Vice President, Human Resources
Paula Swain joined Incyte Corporation, a pharmaceutical company based in Wilmington, Delaware, as Executive Vice President of Human Resources in 2002. Since the company’s inception in 1991, it has grown into a $1.5 billion firm, serving and employing people across the world. “We are able to attract top talent from across the country, from across the fellowship programs, across major universities—MIT, Harvard, Penn, you name it,” said Swain. “[They] come to work here because of the quality of the science, and that is an important core value of the company.” She also adds, “and it is a beautiful place to work.” Prior to her work at Incyte, Swain spent almost 10 years with Du-Pont as Vice President and Senior Vice President of Human Resources, as well as varying roles at Chase Manhattan Bank, Marine Midland Bank, and Delaware Trust Company. Swain holds a BA in psychology from Rockhurst College and graduated from the strategic human resources planning program at Harvard Business School.
14. Andrea Wainer
Executive Vice President, Rapid and Molecular Diagnostics
Medical device company, Abbott Laboratories appointed Andrea Wainer as their Executive Vice President, Rapid, and Molecular Diagnostics in June 2019. Having joined the company in 1997, she's played a major role across the board, within their pharmaceuticals business, including divisional vice president and general manager, renal care. In her current role, Wainer manages two businesses for the company. As a leader in molecular diagnostics, she directs the analysis of DNA and RNA at the molecular level, while also spearheading the world’s leading provider of rapid point-of-care diagnostics. Despite her dual role, she has one goal; to provide clinicians with the tools for better outcomes. “Abbott’s molecular diagnostics can provide the information needed to help guide some of life’s most important health decisions,” says Wainer. “Our accurate, reliable, and quality tests could allow clinicians to make more informed treatment decisions to help improve patient care.” Andrea has a Bachelor’s Degree in accounting from the John M. Olin School of Business, Washington University, St. Louis, Missouri, and a Master’s in Business Administration from the Kellogg School of Management, Northwestern University in Evanston, Illinois.
15. Brinda Balakrishnan, M.D.
Group Vice President, Corporate and Business Development
Brinda Balakrishnan joined BioMarin Pharmaceutical in 2016 as the company’s Group Vice President, Corporate and Business Development. Leading the company’s initiatives on corporate strategy, mergers and acquisitions, and licensing, Balakrishnan supports BioMarin's core business and research in enzyme replacement therapies. With almost 20 years of experience, she has an expansive resume boasting roles at other biotech firms and start-ups. Before joining BioMarin, Balakrishnan was the co-founder and Vice President of Corporate Strategy and Product Development at Vision Medicines, where she notably led the charge in advancing a program for the treatment of Stargardt Disease. She also spent two years as a consultant at McKinsey & Company in the healthcare practice serving clients across small biotech and large pharma. Balakrishnan has a Bachelor of Science from the M.I.T. in Chemical Engineering, a Ph.D. from M.I.T. in Biomedical Engineering and Chemical Engineering, and an M.D. from Harvard Medical School.
16. Annette Tumolo
President, Life Sciences Group
Annette Tumolo is President of the Life Science Group at Bio‑Rad Laboratories. The California-based biotech company, which develops, manufactures and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets, is renowned for its commitment to quality and customer service. Responsible for both the Life Science Group and the company’s Digital Biology Group, Tumolo continues to seek seamless, yet scalable solutions. Having joined Bio-Rad in 1989, she boasts over 30 years of experience across a series of leadership roles, including Executive Vice President and General Manager of the Digital Biology Group, Vice President and Division Manager of the Gene Expression Division, and Business Unit Manager of the Molecular Biology Business Units. Tumolo earned a Bachelor of Science from Rutgers University as well as a Master of Science from Michigan State University. Bio-Rad recently announced the launch of the first commercially available test for determining the coexistence of the STEC virus genes in a single bacterium, dd-Check STEC Solution.
17. Kolleen Kennedy
Varian Medical Systems
President, Proton Solutions and Chief Growth Officer
In October 2018, Kolleen T. Kennedy was named President of Proton Solutions at Varian Medical Systems, a division formerly called Particle Therapy, and Chief Growth Officer. Responsible for developing Varian Proton Solutions offerings as well as managing the company’s Acquisition Integration Office, Strategic Program Management organization and Customer Experience initiatives, Kennedy is a key member of the team. She joined Varian in 1997 and has since gone on to be recognized for her innovative solutions. From 2005 to 2011, Kennedy worked as vice president and general manager of the Customer Support Services (CSS) organization. With her leadership, Varian’s CSS organization was rated the #1 service provider among linear accelerator manufacturers every year by IMV, Ltd., an independent healthcare market research firm that analyzes service trends. She currently serves on the Board of Directors for the Wayne State University Foundation as well as the Union for International Cancer Control (UICC) World City Cancer Challenge Board.
18. Paula Dowdy
Senior Vice President & General Manager, Commercial Operations - EMEA
Since joining the global leader in DNA sequencing and array-based technologies in August 2016, Paula has reorganized the business, identified new markets, and returned Europe, Middle East, and African regions to sustainable growth. Notably, Dowdy was a key part of the senior team behind the launch of NovaSeqTM, Illumina’s new sequencing system. With a proven track record of leadership, insight, and execution, as well as her passion for delivering customer success, Dowdy has been a vital part of the company's progress. Prior to her appointment to Illumina, she worked for Cisco in a variety of senior sales, services and strategy roles, most recently as senior vice president for the Cloud, Software & Managed Services unit where she successfully led Cisco product, software and services groups for virtually all customer segments. Paula holds an MBA degree from Pepperdine University and a Bachelor of Arts degree from the University of California, Berkeley.
19. Darlene Solomon, Ph.D.
Senior Vice President and CTO
Senior Vice President and Chief Technology Officer for Agilent Technologies, Darlene Solomon is responsible for developing the company’s long-term technology strategy and managing the alignment of Agilent’s objectives with its centralized R&D activities. She worked at Hewlett-Packard Laboratories in 1984 as a research scientist until 1999, when Agilent was spun off from HP. Here, she became responsible for Research and Development/Technology for the company’s Life Sciences and Chemical Analysis business and has since commanded an array of roles. She was promoted to Vice President and Director of Agilent Laboratories in 2003 and has been Agilent Technologies' Chief Technology Officer and Senior Vice President since 2006. Darlene received the YWCA Tribute to Women and Industry Award in 2004 and was named to Diversity Journal’s Women Worth Watching in 2007. In 2008, she was named one of Corporate Board Member’s 50 Top Women in Technology, and in 2017, she was elected to the National Academy of Engineering.
20. Anne White
Senior Vice President and President, Lilly Oncology
In September 2018, industry veteran Anne White was elected to be Senior Vice President and President at Eli Lilly Oncology. The Indianapolis pharmaceutical company is a global leader in creating high-quality medicines, improving the understanding and management of disease, and giving back to communities through philanthropy. She has more than 25 years of experience in the pharmaceutical industry and has held various leadership positions in oncology, neuroscience, infectious disease drug development, and process transformation. White has also been recognized as a champion for women in science, especially in her efforts to mentor and support women in the workplace. Working previously as vice president of portfolio management for Lilly’s Chorus and next-gen R&D units, White has also held positions at Tigris Pharmaceuticals and in biotech, having founded and led a startup company in oncology drug development with partnerships with the Moffitt Cancer Center and the National Cancer Institute. She holds a Bachelor's Degree in engineering from the University of Michigan.
21. Ann Powell Judge
Senior Vice President, Chief Human Resources Officer
Ann Powell Judge left Shire Pharmaceuticals in 2013 to join Bristol-Myers Squibb as their Chief human resources officer. Boasting a wealth of experience in human resources with a specialty in pharma, she's also served as corporate vice president, human resources for Wyeth. Previously, she spent 13 years at The Dow Chemical Company, where she worked in a variety of human resources roles while spending some time living and working in Germany and Switzerland. With over 20 years of broad international human resources experience across multiple industries, Judge is a key player on the senior team. Judge has used her expertise and enthusiasm for people to create a transformative strategy at Bristol-Myers Squibb. The strategy and platform, launched in 2014 after extensive global research and analysis is set to drive the company to the forefront of the industry. For this innovative thinker, it’s about simply medicines to patients who need them. “We have all been touched by serious disease,” said Judge. “I have the opportunity to help drive an organization that does great things for patients. That mission runs through the veins of our BMS workforce.”
22. Marion McCourt
Senior Vice President, Commercial
In 2018, Marion McCourt joined Regeneron, a leading biotechnology company that invents life-transforming medicines for people with serious diseases, as the Senior Vice President and Head of Commercial. "Marion is an accomplished biopharmaceutical executive who brings a track record of success in commercializing products and leading commercial teams," said Leonard S. Schleifer, MD, Ph.D., President and Chief Executive Officer, in a press release. "I have long admired Regeneron for its science-driven culture and patient-first mindset," said McCourt. With over 20 years of experience, McCourt's broad experience in biopharmaceutical management with an emphasis on commercial strategy and execution began at AstraZeneca where she stayed for 12 years. She then moved to Amgen, working as Vice President in U.S. Commercial Operations and Vice President and General Manager, Chief Operating Officer of Medivation, and as President and Chief Operating Officer of Axovant. McCourt holds a B.S. in Biology from Lafayette College.
23. Diane Berry, Ph.D.
Senior Vice President, Global Health Policy and Government and Patient Affairs
In December 2011, Diane Berry joined Sarepta Therapeutics, a biotech company at the forefront of precision genetic medicine, as Senior Vice President of Global Health Policy, Government and Patient Affairs. Previously, she worked for the federal government managing and executing science and technology and public health activities. This included CBRN defense efforts, across the legislative and executive branches. While serving as a Subcommittee Staff Director and Senior Professional Staff Member for the House Committee on Homeland Security, Dr. Berry worked at the Department of Homeland Security in the Office of Health Affairs in leadership roles including Chief Scientist, Director of Threat Characterization and Countermeasures, and Senior Biodefense Advisor. She also previously served as a Senior Science Advisor at McKenna, Long, and Aldridge. Dr. Berry earned a Ph.D. in chemical engineering from Northwestern University and received a B.S. and M.S. in chemical and biochemical engineering from Tufts University.
24. Ana Hooker
Senior Vice President, Operations
In 2015, Ana Hooker was appointed as Senior Vice President of Operations at Exact Sciences, a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Managing all laboratory operations, Hooker also leads manufacturing operations, quality, IT and organizational engineering. A champion for diversity and women in the workforce, she’s an active member within the community, supporting the non-profit Maydm organization that advocates for diversity and inclusion within STEM and supporting youth on a path of success. Ana has an MBA from Westminster College, a BS from Kansas State University and has a background in medical technology, operations, and business. With over 25 years of experience in the clinical laboratory space, she also worked at ARUP Laboratories in Salt Lake City, Utah for over 17 years. She is a member of the Latino Professional Association (LPA), Association of Molecular Pathology (AMP) and the American Society of Clinical Laboratory Science (ASCLS).
25. Natasha Hernday
Senior Vice President, Corporate Development
Natasha Hernday joined Seattle Genetics in 2011 and has since successfully executed numerous technology licensing and platform deals with major pharma partners. Most notably, Hernday was instrumental in the purchase of the company’s manufacturing facility, as well as two major experimental cancer treatments, Tucatinib, and Tisotumab Vedotin, into their pipeline. A seasoned pharmaceutical executive with particular expertise in successfully executing transactions, Hernday has over 25 years of biotech experience previously working at Amgen as Corporate Development Director for 16 years. While in corporate development, she was a senior member of the mergers and acquisitions team, followed by a stint in leading Amgen’s out-licensing efforts and serving on the board of two companies for Amgen’s Venture Fund. In June 2019, Hernday was elected to PDL BioPharma's Board of Directors. Hernday received a BA in Biology from the University of California Santa Barbara and an MBA from Pepperdine University.